ijms-logo

Journal Browser

Journal Browser

Molecular Diagnostics in Neurological Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 347

Special Issue Editor

Special Issue Information

Dear Colleagues,

Neurological diseases remain a leading cause of disability and mortality, imposing a significant social and financial burden worldwide. However, advancements in our understanding of the molecular pathogenesis of these diseases are progressing rapidly. With ongoing technological developments and holistic approaches to translational research, an increasing number of biomarkers at the genomic, transcriptomic (including mRNA), epigenomic, and proteomic levels are being identified. These molecular biomarkers hold immense potential for facilitating diagnosis, predicting prognosis, and guiding treatment strategies for patients with neurological diseases.

The International Journal of Molecular Sciences (IJMS) is launching a Special Issue, titled "Molecular Diagnostics in Neurological Diseases", which aims to provide a comprehensive overview of the current state of knowledge regarding molecular biomarkers for the diagnosis and prognosis of neurological conditions. This Special Issue will emphasize the role of molecular diagnostics in understanding, diagnosing, and managing neurological disorders, with a focus on innovative biomarker discovery across various omics platforms. We invite you to submit your contributions, which address cutting-edge topics such as proteomic, genomic, and metabolomic biomarker identification; integration of multi-omics data to elucidate disease mechanisms; liquid biopsies; and advanced imaging linked to molecular diagnostics. Genetic and epigenetic insights into common and rare neurological diseases, as well as translational studies bridging molecular discoveries to clinical practice, will also be considered.

By fostering discussions on precision medicine, this Special Issue will highlight the application of molecular biomarkers in predicting therapeutic responses, personalizing treatment strategies, and advancing our understanding of neurological disease pathophysiology. Researchers are encouraged to submit original studies, reviews, or short communications that reflect the dynamic interplay between molecular diagnostics and clinical neurology.

Dr. Julián Benito-León
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurological diseases
  • biomarkers
  • translational research
  • precision medicine
  • diagnosis
  • prognosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 426 KiB  
Article
Transient Global Amnesia (TGA): Is It Really Benign? A Pilot Study on Blood Biomarkers
by Fabio Rossini, Tobias Moser, Michael Unterhofer, Michael Khalil, Rina Demjaha, Cansu Tafrali, Maria Martinez-Serrat, Jens Kuhle, David Leppert, Pascal Benkert, Johannes A. R. Pfaff, Eugen Trinka and Slaven Pikija
Int. J. Mol. Sci. 2025, 26(6), 2629; https://doi.org/10.3390/ijms26062629 - 14 Mar 2025
Viewed by 235
Abstract
We aimed to determine whether transient global amnesia (TGA) is associated with alterations in central nervous system (CNS) injury biomarkers—serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP). In a prospective cohort of TGA patients, blood samples were obtained within [...] Read more.
We aimed to determine whether transient global amnesia (TGA) is associated with alterations in central nervous system (CNS) injury biomarkers—serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP). In a prospective cohort of TGA patients, blood samples were obtained within 24–48 h of TGA onset (t0) and 6 weeks thereafter (t1). We assessed sNfL and sGFAP levels using the highly sensitive single-molecule array assay and calculated Z-scores adjusted for age, gender, and body mass index (BMI). Demographics, electroencephalography (EEG), and cerebral magnetic resonance imaging (cMRI) findings were also collected. A total of 20 patients were included (median age: 66 years, 70% women). No significant changes in sNfL or sGFAP levels associated with TGA at t0 and t1 were observed. Median sNfL Z-scores were 0.45 (interquartile range [IQR] −0.09, 1.19) at t0 and 0.60 (IQR −0.61, 1.19) at t1. Median sGFAP Z-scores were 0.27 (IQR −0.45, 0.76) at t0 and 0.44 (IQR −0.27, 0.75) at t1. Similarly, in the subgroup of patients with diffusion-weighted imaging (DWI)-positive hippocampal lesions (n = 5/20[25%]), no elevations in blood biomarkers were detected. Our pilot study on neurological blood biomarkers supports the benign nature of TGA, indicating that no CNS tissue damage occurs. Full article
(This article belongs to the Special Issue Molecular Diagnostics in Neurological Diseases)
Show Figures

Figure 1

Back to TopTop